Company Filing History:
Years Active: 2022
Title: Urvi Aras: Innovator in Autoimmune Disease Treatment
Introduction
Urvi Aras is a notable inventor based in Kendall Park, NJ (US), recognized for his contributions to the field of autoimmune disease treatment. With a focus on innovative methods, he has made significant strides in developing therapies that target specific medical conditions.
Latest Patents
Urvi Aras holds 1 patent for his work titled "Methods of treating autoimmune disease using a domain antibody directed against CD40L." This patent outlines methods for treating various autoimmune diseases, including primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis. The invention involves antibody polypeptides that specifically bind to human CD40L without activating platelets. The methods may include at least one administration cycle with doses ranging from about 75 mg to about 1500 mg, ultimately normalizing platelet counts in human patients.
Career Highlights
Urvi Aras is currently employed at Bristol-Myers Squibb Company, where he continues to advance his research and development efforts in the pharmaceutical industry. His work is pivotal in addressing critical health challenges associated with autoimmune diseases.
Collaborations
Urvi collaborates with esteemed colleagues, including Marek Honczarenko and Vaishali Shah, who contribute to the innovative environment at Bristol-Myers Squibb Company.
Conclusion
Urvi Aras exemplifies the spirit of innovation in the medical field, particularly in the treatment of autoimmune diseases. His patent and ongoing work at Bristol-Myers Squibb Company highlight his commitment to improving patient outcomes through targeted therapies.